Changes in Hong Kong stocks | Yuanda Pharmaceutical (00512) opens more than 3% higher, and the world's first “zero-radiation” intelligent nuclear drug factory will be officially put into operation in June

The Zhitong Finance App learned that Yuanda Pharmaceutical (00512) opened more than 3% higher. As of press release, it had risen 3.08% to HK$8.69, with a turnover of HK$7.9687 million.

According to the news, following progress in the development of a number of innovative global nuclear drugs, on the evening of May 18, Yuanda Pharmaceutical, the leading nuclear drug company, once again received significant benefits. The company issued an announcement stating that its global nuclear drug R&D and production site in Wenjiang, Chengdu has obtained a Class A “Radiation Safety License” issued by the Ministry of Ecology and Environment and will be officially put into operation in June 2025. The base was signed at the end of 2022, and the EIA was fully launched in April 2023. Construction permission was obtained in November of the same year. The main ceiling was achieved in only 5 months, setting a new industry construction record in a two-year cycle, and is currently one of the smart factories with the most complete range of nuclides and the highest degree of automation in the world.

According to the announcement, Yuanda Pharmaceutical's global nuclear drug R&D and production base in Wenjiang, Chengdu is positioned as a global highland of innovative nuclear drug industrialization. It is the world's first “zero radiation” intelligent nuclear drug factory, and the full-process radiation monitoring system meets nuclear power safety standards.

The base covers an area of 50 acres, with a total construction area of 25 acres, with a total construction area of over 26,000 square meters. The total planned investment is over 3 billion yuan, focusing on core areas such as isotope process development and preparation, nuclear drug coupling technology, and automated labeling technology, covering early nuclear drug research, process development, quality research, non-clinical research, intelligent production and accurate distribution. It is currently one of the most diverse and automated smart factories with the highest degree of automation in the world. Its nuclear drug production workshop is equipped with 14 high-standard GMP production lines to achieve independent production of various isotopes such as 18F, 64Cu, 89Zr, etc., while reserving production lines for alpha nuclide drugs to fully meet the company's multi-variety and large-scale preparation needs for therapeutic and diagnostic nuclear drugs.